Dapagliflozin Effects on Hypoglycemia

Launched by UNIVERSITY OF CALIFORNIA, SAN DIEGO · Oct 11, 2018

Keywords

ClinConnect Summary

The purpose of this research study will be to test and evaluate if dapagliflozin has an effect on the amount of glucagon (a hormone produced by the pancreas and stomach that stimulates liver glucose production) produced by the body and if that change will improve recovery time from hypoglycemia (low blood sugar) in participants with Type 1 Diabetes. The study is a blinded, placebo-controlled, crossover design, where participants will receive dapagliflozin during one treatment period and placebo during a separate treatment period with neither the study team nor participants knowing what they...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Signed and dated written informed consent by the date of Visit 1 in accordance with Good Clinical Practice (GCP) and local legislation
• • 2. Male or female patient receiving insulin for the treatment of documented diagnosis of T1DM for at least 1 year at the time of Visit 1
• • 3. Non-fasting C-peptide \< 0.7 ng/mL at Visit 1
• • 4. HbA1c ≤ 10.0% at Visit 1
• 5. Based on the Investigator's judgment patient must have a good understanding of his/her disease and how to manage it, and be willing and capable of performing the following study assessments (assessed at Visits 1):
• • patient-led management and adjustment of insulin therapy
• • reliable approach to insulin dose adjustment for meals, such as carbohydrate counting
• • reliable and regular home-based blood glucose monitoring
• • be able to perform ketone sample measurement when feeling ill and/or nauseated
• • implementation of an established "sick day" management regimen
• • 6. Age ≥ 18 and ≤ 70 years at Visit 1
• • 7. Body Mass Index (BMI) of 18.5 kg/m2 to 35.0 kg/m2 at Visit 1
• • 8. eGFR ≥ 60 mL/min/1.73m²
• • 9. Patients must be able and willing to perform study assessments
• Exclusion Criteria:
• • 1. History of T2DM, maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis
• • 2. Pancreas, pancreatic islet cells or renal transplant recipient
• • 3. T1DM treatment with any other antihyperglycemic drug (e.g. metformin, alpha- glucosidase inhibitors, SGLT-2 inhibitors, pramlintide, inhaled insulin, pre-mixed insulins, etc.) within 30 days of run-in (visit 2)
• • 4. Occurrence of severe hypoglycemia involving coma and/or seizure that required hospitalization or hypoglycemia-related treatment by an emergency physician or paramedic within 3 months prior to Visit 1 or Visit 2
• • 5. Occurrence of DKA within 3 months prior to Visit 1 or Visit 2
• • 6. Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or transient ischemic attack (TIA) within 3 months prior to Visit 1 or Visit 2
• • 7. Indication of liver disease, defined by serum levels of either alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase above 3 x upper limit of normal (ULN) at Visit 1
• • 8. Current signs and symptoms of anemia accompanied by a hemoglobin laboratory value at or below 10.0 g/dL at screening.
• • 9. Eating disorders such as bulimia or anorexia nervosa
• • 10. Treatment with systemic corticosteroids within 30 days of run-in (visit 2), or planned initiation of such therapy at Visit 1 or Visit 2. Inhaled or topical use of corticosteroids (e.g. for asthma/chronic obstructive pulmonary disease) is acceptable.
• • 11. Medical history of cancer or treatment for cancer in the last five years prior to Visit 1. Resected basal cell carcinoma considered cured is exempted.
• • 12. Women who are pregnant, nursing, or who plan to become pregnant while in the trial
• • 13. Intake of an investigational drug in another trial within 30 days prior to Visit 1
• • 14. Patient not able to understand and comply with study requirements, based on Investigator's judgment
• • 15. Any other clinical condition that, based on Investigator's judgment, would jeopardize patient safety during trial participation or would affect the study outcome (e.g. immunocompromised patients who might be at higher risk of developing genital or mycotic infections, patients with chronic viral infections etc.)